News

SITC 2024: Elucidating the Therapeutically Relevant Mechanisms of TROP2 in Breast Cancer

SITC 2024: Adding IL-4 Inhibitor to PD-1 Inhibitor Therapy for ER-Positive Breast Cancer

SITC 2024: CRISPR Editing Yields New B-Cell Strategies for Treating HER2-Positive Breast Cancer

SITC 2024: Wnt Inhibitor Emerges as Regulator of Breast Cancer Progression

SITC 2024: Overcoming PARP Inhibitor Resistance in BRCA1-Mutated Breast Cancer

Novel CKD4/6 Inhibitor Under Study in Advanced Breast Cancer

Radiotherapy Strategy for Enhancing Immunotherapy for Triple-Negative Breast Cancer

Ivonescimab Plus Chemotherapy for Triple-Negative Breast Cancer

Lymphedema and Hypofractionated Nodal Regional Irradiation

Abemaciclib Plus Endocrine Therapy Under Study in Advanced Breast Cancer

Novel CDK2/4 Inhibitor Under Study in Metastatic Breast Cancer

Therapeutic Implications of Pathogenic Variants in Metastatic Breast Cancer

Multilevel Chronic Stress and the Tumor Immune Environment: Is There a Connection?

Novel Genomic Test Under Study in Early-Stage Triple-Negative Breast Cancer

Could Manuka Honey Be Beneficial in Treating Estrogen-Positive Breast Cancer?

ASTRO 2024: Single-Fraction, Partial-Breast Irradiation in Hormone-Sensitive Breast Cancer

Inavolisib Combination Therapy Approved by FDA for Advanced Breast Cancer Subtype

Mental Health Screening for Female Veterans With Breast Cancer

ASTRO 2024: French Trial of Radiotherapy Plus T-DXd in HER2-Positive Breast Cancer

ASTRO 2024: Hypofractionation With Simultaneous Integrated Boost in Breast Cancer

ASTRO 2024: Hypofractionated vs Conventional Regional Nodal Irradiation in Treating Invasive Breast Cancer

ASCO Quality 2024: Benefits of Acupuncture in Treating Chemotherapy-Induced Peripheral Neuropathy

ASTRO 2024: Noninferiority Trial of Hypofractionated Radiation Schedules After Mastectomy

ESMO 2024: Chemotherapy-Free Immunotherapy for Immunogenic Triple-Negative Breast Cancer

ASCO Quality 2024: Can Socioeconomic Status Influence Breast Cancer Severity?

ESMO 2024: 4-Year NATALEE Outcomes Support Ribociclib-Based Therapy in Early Breast Cancer

ESMO 2024: Supplementary Biomarker Analyses of DAISY Trial of T-DXd in Metastatic Breast Cancer

ESMO 2024: Adding SBRT to Immunotherapy and Chemotherapy in High-Risk Breast Cancer

FDA Amends Mammography Quality Standards Act

ESMO 2024: Personalized, Remote Physical Activity and Quality of Life for Breast Cancer Survivors

Early, High-Risk Breast Cancer: Expanded FDA Approval for CDK4/6 Inhibitor–Based Therapy

ESMO 2024: DESTINY-Breast12 Supports T-DXd in Patients With HER2-Positive Breast Cancer and Brain Metastases

ESMO 2024: New TROP2 Antibody-Drug Conjugate Under Study in Metastatic Breast Cancer

ESMO 2024: 10-Year Trial Update on TILs and Overall Survival in Early-Stage Breast Cancer

Can Early Patient Education Help to Manage Adverse Effects From Breast Cancer Treatment?

Factors Influencing Axillary Lymph Node Metastasis in Pure Mucinous Breast Carcinoma

Can Smartphone Apps Improve Medication Adherence in Patients With Breast Cancer?

Breast Cancer Subtypes: How Do Epithelial Cells and Macrophages Interact?

Racial Disparities and Impact of COVID-19 on Clinical Outcomes in Breast Cancer

I-SPY2 Trial: Response-Predictive Subtypes of Breast Cancer

Which Has Fewer Complications: Minimal Access or Conventional Nipple-Sparing Mastectomy?

How Best to Use Radiotherapy for Early-Stage Breast Cancer: 30-Year Trial Update Offers Clues

High-Risk, Early-Stage Breast Cancer: Tailored Dose-Dense vs Standard Adjuvant Chemotherapy

Ways to Improve Breast Cancer Screening Among Women Experiencing Homelessness

With Machine Learning, Researchers Improve Potential Blood-Based Breast Cancer Test

Why Men Should Be Screened for BRCA1/2 Variants

Insomnia and Inflammation in Breast Cancer Survivors: Tai Chi and Cognitive Behavioral Therapy

Cryoablation as an Alternative to Surgery for Clinical Trial–Ineligible Patients With Breast Cancer

Chemotherapy for Breast Cancer: Link to Gut Microbiome Disruption and Cognitive Decline?

TIL-Based Computational Pathology Biomarker for Ductal Carcinoma In Situ

Genetic Testing Guidelines for Patients With Breast Cancer

Treatments and Mortality Among Female Childhood Cancer Survivors With Subsequent Breast Cancer

NATALEE Trial: Ribociclib Plus NSAI in Node-Negative Breast Cancer Subgroup

Easing the Effects of T-DXd: Electronic Symptom Tracking Tested in PRO-DUCE Trial

Potential Prognostic Cellular Biomarker Investigated for Stage I Triple-Negative Breast Cancer

Genomic Alterations and Targeted Treatment by Race in Metastatic Breast Cancer

Palbociclib-Based Therapy for HER2-Positive and PAM50 Luminal Advanced Breast Cancer

Antibody-Drug Conjugate ARX788 Under Study in HER2-Positive Breast Cancer

Breast Cancer Treatment: FDA Approves Liquid Form of Thiotepa

ASCO 2024: Targeted Triplet for Leptomeningeal Metastasis in HER2-Positive Breast Cancer

ASCO 2024: Should PI3K Inhibitor Become Part of Standard of Care for Breast Cancer Subtype?

ASCO 2024: Prognostic Value of Hormone Receptor Status and Tumor Subtypes in BRCA-Positive Breast Cancer

Advanced Breast Cancer: Is Abemaciclib Plus Endocrine Therapy of Benefit After Disease Progression?

ASCO 2024: Adjuvant Use of Avelumab in High Risk, Early-Stage Triple-Negative Breast Cancer

ASCO 2024: Phase II Survival Update of Palbociclib Plus Exemestane in Metastatic Breast Cancer

ASCO 2024: MUC1 Vaccine Plus Neoadjuvant Chemotherapy for Early-Stage Breast Cancer

ASCO 2024: Prognostic Role of ctDNA in the monarchE Breast Cancer Trial Population

ASCO 2024: Results From EV-202 of Enfortumab Vedotin in Breast Cancer Cohorts

ASCO 2024: Taxane-Free First-Line Regimen for Advanced HER2-Positive Breast Cancer

ASCO 2024: Is Adjuvant Endocrine Therapy Necessary for ER-Low Breast Cancer?

ASCO 2024: Novel Antibody-Drug Conjugate Under Study in Advanced Triple-Negative Breast Cancer

ASCO 2024: Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer

ASCO 2024: DESTINY-Breast06 Update on T-DXd vs Chemotherapy in Metastatic Breast Cancer

Use of Everolimus in Advanced ER-Positive, HER2-Negative Breast Cancer: Molecular Features Influence Prognosis